U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Aquavit will officially unveil the Dermatox and Microtox programs at the Annual American Academy of Dermatology, the world's largest dermatology conference scheduled from March 25-29, 2022, in Boston, MA
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
Vault PromoMats helps life sciences companies speed the creation, review, and distribution of compliant content. Built-in digital asset management enables content reuse and reduces spend on promotional materials
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
Subscribe To Our Newsletter & Stay Updated
